Form 4: SI-BONE CEO Laura Francis Reports RSU Grants, Tax-Related Share Sales

SI-BONE CEO Laura Francis reported the grant of 229,481 restricted stock units and the sale of 93,475 shares to cover tax obligations.

Summary

• Laura Francis, CEO and Director of SI-BONE, Inc. (SIBN), was granted 229,481 restricted stock units (RSUs) on February 16, 2026.
• Of these, 114,741 RSUs will vest over four years in quarterly installments beginning February 15, 2026.
• The remaining 114,740 RSUs (two grants of 57,370 each) will vest over three years based on the Issuer's Total Shareholder Return (TSR) performance against a peer group.
• On February 17, 2026, Francis sold a total of 93,475 shares of common stock in multiple transactions at weighted average prices ranging from $15.2866 to $15.4362.
• These sales were non-discretionary "sell to cover" transactions to satisfy tax withholding obligations related to the vesting of restricted stock units.
• Following these transactions, Francis directly beneficially owns 544,369 shares (including 414,439 shares issuable from RSU settlements) and indirectly owns 351,319 shares through The David & Laura Joint Rev Tr.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event. The significant RSU grants align executive incentives with long-term company performance, while the share sales are non-discretionary tax-related events, not indicative of a lack of confidence.

Positives

• Grant of 229,481 restricted stock units (RSUs) to the CEO aligns management incentives with long-term shareholder value.
• A portion of the RSU grants (114,740 shares) is performance-based, tied to the Issuer's Total Shareholder Return (TSR) relative to a peer group, promoting performance-driven compensation.
• The "sell to cover" transactions are non-discretionary, indicating they are for tax obligations rather than a voluntary reduction in ownership.

Negatives

• The sale of 93,475 shares, even if for tax purposes, represents a reduction in the CEO's direct common stock holdings.

Future Outlook

The vesting schedules for the granted restricted stock units indicate future share issuances to the Reporting Person, contingent on continued service and, for a portion, on the Issuer's Total Shareholder Return performance over three years.

Industry Context

StockSavvy.ai notes that equity compensation, particularly through restricted stock units with performance-based vesting, is a common practice in the medical device industry to incentivize executive leadership and align their interests with long-term company performance and shareholder returns. The 'sell to cover' mechanism for tax obligations is also standard practice for RSU vesting.

Stakeholder Impact

• Shareholders: The RSU grants align the CEO's interests with shareholder value creation, particularly the performance-based awards. The tax-related sales are routine and not indicative of a change in sentiment.
• Employees: The RSU grants are part of executive compensation, which can set a precedent for broader employee incentive programs.

Next Steps

• Vesting of 114,741 restricted stock units in quarterly installments over four years, beginning February 15, 2026.
• Vesting of 114,740 restricted stock units over three years, contingent on the Issuer's Total Shareholder Return (TSR) performance against a peer group.

Key Dates

Recommendation

The filing details routine insider transactions involving RSU grants and subsequent 'sell to cover' sales for tax obligations. These are standard events in executive compensation and do not signal a fundamental change in the company's prospects or the executive's confidence. Therefore, a 'hold' recommendation is appropriate as this filing provides no new information to alter an existing investment thesis.

Keywords

SI-BONE, SIBN, Laura Francis, CEO, Director, Form 4, Restricted Stock Units, RSU, Share Sale, Insider Transaction, Equity Compensation, Sell to Cover, Tax Withholding